logo
Plus   Neg
Share
Email

Sanofi: Libtayo Shows Clinically-Meaningful And Durable Responses In Skin Cancer

Regeneron Pharmaceuticals Inc. (REGN) and Sanofi announced topline data from a pivotal, single-arm, open-label trial for the PD-1 inhibitor Libtayo in patients with advanced basal cell carcinoma who had progressed on or were intolerant to prior hedgehog pathway inhibitor therapy.

Libtayo demonstrated clinically meaningful and durable responses in Second-line Advanced Basal Cell Carcinoma. Regeneron and Sanofi plan regulatory submissions in 2020.

Basal Cell Carcinoma is a skin cancer and is the most common cancer worldwide, with approximately two million new cases diagnosed every year in the U.S. alone.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The media mogul and Billionaire Sumner Redstone passed away on Tuesday at the age of 97, his family's holding company National Amusements said in a statement on Wednesday. He was Chairman Emeritus of ViacomCBS and chief executive officer of National Amusements. Customers in the U.S. are preferring digital or touchless payment methods due to concerns arising from the COVID-19 pandemic, a survey said. According to the survey by Rapyd Financial Network, the coronavirus pandemic has raised health and safety concerns around using cash and coins, and is accelerating the pre-existing trend toward digital transactions. American Airlines has extended its offer to waive change fees for customers who purchase tickets for travel, until December 31, 2020 in response to lower travel demand due to the coronavirus pandemic. This means that the travelers need not pay penalties for changing the origin and destination cities.
Follow RTT